Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ADMP Dry Powder Inhaler plus Pre-filled Syringe solutions.
Nearly 600,000 inhalers were just voluntarily recalled nationwide by GlaxoSmithKline due to "defective delivery system,"
http://www.in-pharmatechnologist.com/Drug-Delivery/Adamis-Looks-to-Dry-Powder-Inhaler-Tech-Following-3m-License-From-3M
https://www.popsugar.com/moms/Recall-Alert-Check-Your-Child-Inhalers-ASAP-43401065
Mylan hit with racketeering suit.
quote: "Big drugmaker Mylan was slapped Monday with a class-action racketeering lawsuit that claims the company engaged in an illegal scheme to dramatically increase the list price of its EpiPen anti-allergy device over the past decade.
The suit alleges that the "skyrocketing" list price of EpiPen for consumers was the result of Mylan's payments of rebates to pharmacy benefit managers — including CVS Caremark, Express Scripts and Optum Rx — which handle prescription drug benefit programs for insurance plans.
The suit claims violations of consumer protection laws of all U.S. states, as well as a violation of the Racketeer Influenced and Corrupt Organizations Act. If granted class-action status, the suit would cover all consumers.
The suit says Mylan only disclosed that its price increases for EpiPen were due to the rebate payments to the PBMs last summer, after outrage exploded over the fact that a two-pack of the auto-injector devices was selling for more than $600.
A decade earlier, it cost consumers paying list price about $90 for EpiPen, which is used to treat a potentially fatal allergic reaction known as anaphylaxis. Since then Mylan had increased the list price of the device 17 times, the suit said.
The suit, filed in U.S. District Court in Seattle, noted that when EpiPen prices were increasing most dramatically, some other companies tried to introduce competing devices.
But those companies never succeeded in displacing the market dominance of EpiPen because they did not pay the same level of rebates that Mylan was paying the pharmacy benefit managers, the suit said.
"Mylan has tried every trick in the book to avoid taking accountability to the millions of people who are living without the EpiPen they need to prevent a life-threatening allergic reaction," said Steve Berman, managing partner of Hagens Berman, which represents the three named plaintiffs in the suit.
"Despite the fiction that Mylan has tried to sell the public, and sell Congress, the numbers don't lie — Mylan has been the motivating force behind the jaw-dropping 574 percent EpiPen price hike," Berman said. "Mylan is no victim."
A spokeswoman for Mylan had no immediate comment on the lawsuit.
Berman told CNBC that the list price charged for EpiPen has "become a completely phony price," that bears little relationship to the relatively minor cost of producing EpiPen.
Most EpiPen customers have some form of insurance that covers all or part of the cost of their purchase, he said.
But a small fraction of all consumers pay the list price for the device, either because they have no insurance, or because they are buying multiple packs of EpiPens and only one pack is covered by their health plan.
Berman said Mylan and the PBMs did not have true arms-length dealings in negotiating the price of EpiPen paid by the PBMs because both sides had an interest in driving up the price to increase their profits. That, in turn, led to the list price of EpiPen being artificially inflated, Berman said.
"When you scheme to drive up the list price beyond any relationship to cost, that's illegal," Berman said.
Mylan is the only named defendant in the suit. But the suit also claims that CVS Caremark, Express Scripts and Optum Rx participated in the scheme, "sharing the common purpose of inflating the list price of EpiPen, through a pattern of racketeering activity."
The PBMs, the suit alleged, "knowingly made material misstatements to health care payers, plan members, and the general public" about the actual price of EpiPen, the extent to which the published price differed from the actual price, and the extent to which they and Mylan "negotiated the rebates discounting the list price of EpiPen for a purpose other than the PBMs' own enrichment."
"Berman said he did not sue the PBMs for "strategic" reasons."
Dan Mangan
$ADMP stands to benefit from Mylan's EpiPen recall
IMO Patients get a better deal.
quote:"Analysts at Maxim see Adamis' syringe as "a better, more user-friendly product (design wise) versus EpiPen, Adrenaclick and AuviQ. The market opportunity is large. Even with just moderate market share assumptions,the pre-filled syringe becomes a significant product,"
"Mylan recalls 81,000 EpiPens outside US after reports of failure"
ADMP contribution to helping lower cost for patients is a plus. A win/win for shareholders and patients.
'laker5' sorry for the mis-understanding. Meant no harm to you.
"Great reversal in the stock today. Very-bullish action.
Unfortunate for the users but it can't hurt Admp."
https://www.statnews.com/2017/03/21/epipen-recall-mylan/
http://www.stockta.com/cgi-bin/analysis.pl?symb=ADMP&cobrand=&mode=stock
'North40000'-thankyou, Here is some information about your statement.
http://www.businessinsider.com/trump-planning-to-nominate-scott-gottlieb-as-fda-commissioner-2017-3
I'm not asking you to follow me. However, do you understand me about the quarterly chart?
Like $ADMP quarterly chart to $16.00-$18.00 twice, they say, "three times is a charm".
Normal profit retrace with continued $ADMP uptrend. IMO
$ADMP Bounce uptrend to $10.00 Anyone up for that?
$ADMP Very Bullish (0.53) Bullish (0.45) Very Bullish (0.66) Very Bullish (0.50)
"Thank You and Happy Hunting
Bret Jensen
Founder, Biotech Forum & Insiders Forum
Disclosure: I am/we are long ADMP"
$ADMP Fill in the Gap $10-16
Partner/approval is the way to financial success. IMO
Thanks "dude iligence" $ADMP 52 Week High $10.98
Best to all involved.
Bullish Bounce $10.00 turnaround target. $ADMP
Bullish (0.31) Bullish (0.26) Bullish (0.35) Bullish (0.32)
BullishAnalysis Overall Short Intermediate Long
Bullish Bullish Bullish Bullish
ADMP Jan-26-2017
http://www.stockta.com/cgi-bin/analysis.pl?symb=ADMP&cobrand=&mode=stock
Zacks: Adamis-Pharmaceuticals-Corporation (ADMP) Given $7.50 Consensus Target-Price by Brokerages
Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
http://dailyquint.com/2017-01-20-zacks-adamis-pharmaceuticals-corporation-admp-given-7-50-consensus-target-price-by-brokerages/
Zacks: Adamis-Pharmaceuticals-Corporation (ADMP) Given $7.50 Consensus Target-Price by Brokerages
Zacks Investment Research reports. Two equities research analysts have rated the stock with a strong buy recommendation.
http://dailyquint.com/2017-01-20-zacks-adamis-pharmaceuticals-corporation-admp-given-7-50-consensus-target-price-by-brokerages/
$ADMP Why Adamis Tops-Impax-Syringe at CVS-Health - Barron's
www.barrons.com/articles/why-adamis-tops-impax-syring... Proxy Highlight
18 hours ago ... Recall that Adamis (ticker: ADMP) announced the resubmission of the NDA. ... revenue set to build, we see Adamis as poised for a breakout year in 2017. ... standards in the market, and it performed better than all of them.
New buy rating for ADMP. link below
https://www.marketbeat.com/stocks/NASDAQ/ADMP/?RegistrationCode=SocialMedia-direct
Too late, the price-dropped just after you-said-it.
Could you go to jail for saying that?
Swing-Bounce up finish green ok with me....
I have three photos of Maxims new ADMP $10.00 target reiteration.
ADMP Announces-FDA-Acceptance of Pre-Filled-Syringe Resubmission
https://finance.yahoo.com/news/adamis-pharmaceuticals-announces-fda-acceptance-140000480.html
Reiteration of target $10.00 by Maxim. Buy
$ADMP in the big picture. 1/13/2017
https://drive.google.com/file/d/0Bwv8fVUzSRsJd2txbHVHcDlfZTQ/view
$ADMP "Adamis has refiled another potential rival. On-top-of-that, “at least one large distributor is apparently not carrying” Mylan’s generic version, Gal wrote."
Quote: from ACInvestorBlog Potential Powerful Breakout "Adamis Pharmaceuticals Corp (NASDAQ:ADMP) has been trading a very tight range for a few days right up at resistance. If it clears this key resistance the move may be powerful. The consolidation and compression that has been going on in the last days is very healthy. Long setup on watch."
http://ac-investor.blogspot.com/2017/01/my-watchlist-for-friday-january-06.html
$ADMP gets two Buy ratings: Consensus Target $7.50-$10.00
see link below to see if information above is true
https://www.marketbeat.com/stocks/NASDAQ/ADMP/?RegistrationCode=SocialMedia-StockTwits
With OCAT-billionaire Mario Gabelli owning more than 5%, it beats being a naked short.
Some say, to buy, hold and "untender" shares. It's been said, "untendering shares is easy". Did anyone see the new letter in support of shareholders?
buy, hold and "untender" shares
It has been said that "we-still-own-53%-of-the-shares."
With two victories under the belt and a third underway "making way".
Nort40000, after listening to the whole JNJ event, they said that they are in position to aquire and are loaded with cash at any given moment they choose anything that would greatly add to their totals.
I did see JNJ and Matt Vincent in a discussion before in a session about partnering.
Great Link North40000 !!! Thankyou for sharing.
So true art2426. "how about the fact that the tender has failed twice already and who is to say that some who did tender won't rescind."
"If you haven't-tendered, you need not do anything; if you already HAVE tendered, you can withdraw the tender (un-tender)"
JNJ, what an interesting possibility, ACT/OCAT has had close contact in years past with JNJ.
"The more times we buy the more chance that a competing bid will present itself."
Two great wins against tendering, great science with a plan, billionaire on board, Vanguard and Blackrock on board, thousands of briliant minds working together. A few tweaks and changes.
It's too late to get understanding after your dead you've made your grave. The dead know nothing, "It's not for them to know".
Naked shorts caught off guard have to react when caught leaning. There are other types of singers with purpose, not all are fat ladies. Keeping the OCAT IP ready is alive with opportunity. Giving conversation with sarcasm would be like a dog licking up it's own vomit.